Lipofol

Quick links to important sections

Lipofol

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipofol

Property Description
Active ingredient Propofol
Form Sterile Oil-in-Water Emulsion
Pharmacological class Intravenous General Anesthetic Agent
Common use Induction and maintenance of general anesthesia or sedation
Origin Synthetic Phenolic Derivative

Identity and Classification

Lipofol is a trade designation for the pharmaceutical substance Propofol, which is categorized as a powerful, short-acting intravenous general anesthetic agent. This medicine belongs to the broad sedative-hypnotic agent class, used primarily to achieve and maintain medically controlled unconsciousness. The active ingredient, Propofol, is a synthetic phenolic derivative (C12H18O) and is classified as a non-barbiturate compound, distinguishing its action and rapid recovery profile from older agents.

Composition and Physical Form

Lipofol is formulated as a sterile, white, oil-in-water emulsion intended exclusively for intravenous injection. It is a single-ingredient product, containing only Propofol as the active component. Because the Propofol molecule is highly lipid-soluble and nearly insoluble in water, the medicine must be suspended in a specialized lipid-based vehicle, a preparation that is necessary for maintaining the drug's stability and ensuring effective delivery into the patient’s bloodstream.

General Purpose and Core Physiological Action

The general purpose of administering Lipofol is to quickly and reliably induce and maintain a state of general anesthesia or deep, controlled sedation for patients undergoing surgical procedures or requiring ventilatory support in critical care. Propofol achieves its effect by functioning as a strong depressant on the central nervous system, where its primary action involves enhancing the function of the inhibitory neurotransmitter GABAA receptors. This mechanism ensures a rapid, reliable hypnotic effect, which results in the controlled unconsciousness required for safely proceeding with medical procedures.

Regulatory References

  1. Propofol - StatPearls - NCBI Bookshelf
  2. Propofol Injection: MedlinePlus Drug Information

What side effects are possible with Lipofol?

Possible Side Effects and Safety Information

The safety profile for Lipofol (Propofol) is formally documented in government regulatory sources, classifying adverse reactions by frequency and physiological system. This profile is defined primarily by its effects as a potent depressant on the central nervous and cardiorespiratory systems.

Frequency-Classified Adverse Reactions

The most commonly documented reactions are generally associated with the initial administration period. Very Common side effects (affecting ge1/10 patients) include pain, burning, or stinging at the injection site. Common reactions (affecting ge1/100 to <1/10 patients) involve hypotension (decreased blood pressure), bradycardia (slow heart rate), transient apnea (temporary cessation of breathing), and certain types of excitation phenomena (e.g., involuntary movements or twitches). Less common adverse events include thrombosis or phlebitis.

Serious Adverse Reactions and Safety Constraints

The regulatory label identifies rare but serious adverse reactions, notably Propofol Infusion Syndrome (PRIS), which is a potentially fatal condition characterized by severe metabolic acidosis and cardiac failure. Other serious documented risks include cardiac arrest and anaphylaxis. Safety documentation mandates that due to the lipid-emulsion formulation, strict aseptic technique must be maintained during handling and administration to prevent the documented risk of microbial contamination and subsequent severe infection.

Population and Exposure Considerations

Official safety information notes specific considerations for certain patient groups. Older adults are documented to be predisposed to a higher incidence and degree of hypotension and apnea. Furthermore, the use of Lipofol for prolonged ICU sedation is contraindicated in certain pediatric patients due to the association with PRIS risk. PRIS itself is an exposure-related risk, linked specifically to high-dose or extended infusions.

Overdose and Emergency Response

The official documentation defines overdose of Lipofol (Propofol) as a medical emergency primarily resulting in the severe exaggeration of the drug’s intended effects: profound cardiorespiratory depression. Clinical manifestations documented in regulatory labeling include apnea (cessation of breathing), arterial hypotension (a significant drop in blood pressure), airway obstruction, and oxyhemoglobin desaturation. Bradycardia and eventual cardiovascular collapse are recognized severe outcomes.

Regulators mandate that immediate medical attention be sought when an overdose is suspected or when any severe cardiorespiratory signs manifest. A critical requirement is the availability of readily available resuscitative facilities for immediate intervention. Management is strictly symptomatic and supportive, as official sources state that no specific antidote exists. Treatment procedures include providing artificial ventilation and administering intravenous fluids and vasopressors to manage circulatory depression.

A specific life-threatening condition documented is the Propofol Infusion Syndrome (PRIS), associated with prolonged, high-dose exposure. PRIS is characterized by metabolic acidosis, rhabdomyolysis, and acute renal failure. Immediate discontinuation of the infusion and continuous monitoring are required for suspected cases. Regulatory information also notes that elderly patients and those with ASA Physical Status III or IV have an increased risk of severe cardiorespiratory depression.

Therapeutic Uses of Lipofol

What Lipofol Treats: Main Uses and Benefits

Lipofol is used in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is appropriate.

This medication is applied in addressing conditions characterized by temporary physiological imbalance, specifically across several therapeutic domains: it may assist with inducing and maintaining general anesthesia, it is commonly used for managing sustained deep sedation in critically ill patients, and it supports the use of short-term sedation for various diagnostic and surgical procedures.

For patients, the primary benefit is the assistance provided in achieving a desired state of controlled unconsciousness and amnesia for procedures, thereby contributing to easing the overall symptom load when symptoms are more noticeable. This is particularly relevant in scenarios where additional management of discomfort is required.

“The medication helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.”


Quick Fact: Relief for Acute Agitation

Lipofol is considered relevant for easing symptoms related to heightened physiological activity, especially acute agitation and distress in intubated patients receiving mechanical ventilation, where it assists with patients' ability to tolerate life-sustaining support.

Regulatory References

  1. NIH StatPearls overview on Propofol

Eligibility and Restrictions for Use

Who can and cannot use Lipofol?

The use of Lipofol (Propofol) is governed by strict population eligibility rules defined in official government labeling. The medicine is primarily approved for use in adults for general anesthesia, ICU sedation, and procedural sedation. Pediatric patients (typically 3 years and older) are eligible for general anesthesia.


Absolute Contraindications

Use is contraindicated in patients with known hypersensitivity to Propofol or any component of the emulsion, such as soybean or egg products. A major regulatory restriction is the contraindication of Lipofol for sedation in pediatric patients under 16 years of age in the Intensive Care Unit (ICU). The medicine must also not be used in patients with specific disorders of fat metabolism.


Restricted and Conditional Use

Use is formally not recommended during obstetric anesthesia (delivery/C-section) and lactation. Certain groups require conditional use or heightened monitoring, including older adults (due to increased sensitivity) and patients with severe, pre-existing conditions like cardiac disease or severe hypovolemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes clinically significant interactions between Lipofol and several medicinal products and substance categories. This information is critical for healthcare professionals to manage combination therapy safely.

Documented Interacting Substance Categories

Combinations with HMG-CoA Reductase Inhibitors (statins), Macrolide Antibiotics, Azole Antifungals, and the immunosuppressant Cyclosporin are officially noted to enhance the potential for serious adverse effects, including myositis and hepatotoxicity. Additional interaction concerns exist with Fibrates, Resins (e.g., Cholestyramine), and certain Oral Hypoglycemic Agents.

Specific Interacting Medicines and Mechanisms

  • Resins may impair the absorption of many concurrently administered oral medications. Spacing the administration of Lipofol and resins is required to prevent reduced effectiveness of the co-administered drug.
  • Fibrates have documented interactions with Warfarin, requiring enhanced monitoring when used together.
  • Probucol may interact with specific Antidysrhythmics and Phenothiazines.

Interaction-Related Constraints

Official documents define certain drug combinations as highly clinically significant, necessitating they be avoided entirely. Combinations with moderately clinically significant risks should be used only with caution and under special circumstances. These constraints are based on the documented potential to enhance the risk of muscle and liver toxicity when co-administered with certain drug classes.

Mechanism of Action

The mechanism of action for Lipofol centers primarily on modulation of inhibitory neurotransmission within the central nervous system. The compound, due to its high lipophilicity, rapidly traverses the blood-brain barrier and distributes into highly perfused neuronal tissues. Lipofol functions as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor. By binding to a specific site on the receptor, the molecule increases the duration of the chloride channel opening upon GABA binding. This enhanced chloride ion conductance across the postsynaptic neuronal membrane results in hyperpolarization of the neuron. The resulting electrical state shift diminishes the probability of an action potential firing, which contributes to an overall reduction in neuronal excitability. Downstream effects of this primary mechanism include a reduction in cerebral metabolic oxygen consumption and cerebral blood flow. Furthermore, the drug engages secondary mechanisms, including inhibition of the N-methyl-D-aspartate (NMDA) receptor and activation of glycine receptors, further shaping the cascade of inhibitory effects that define its pharmacodynamic profile.

Dosage and Administration Information

Lipofol (Propofol) is an intravenous anesthetic agent with strict instructions governing its use, administration, and preparation.

Official Administration Guidelines

Category Official Instruction (Based on Regulatory Guidelines)
Route of Administration Strictly Intravenous (IV), administered as a bolus injection or a continuous infusion.
Dosing Schedule The dose must be titrated to the desired level of effect. Induction (Adults <55 years): typically 1.5 to 2.5 mg/kg IV. Maintenance (Infusion): 50 to 200 mcg/kg/min (or 3 to 12 mg/kg/hour). ICU Sedation: 5 to 50 mcg/kg/min.
Age-Group Rules Older Adults: Require reduced doses and slower administration (e.g., 20 mg increments every 10 seconds) to avoid adverse effects. Pediatrics: Approved for induction >= 3 years and maintenance >= 2 months; use for ICU sedation is not recommended for patients 16 years and younger.
Preparation Requirements Asepsis: Strict aseptic technique must be maintained during handling. Dilution: Must only be diluted with 5% Dextrose Injection, to a concentration no less than 2 mg/mL.

Procedural Instructions

Lipofol must be administered under the direct supervision of medical personnel trained in anesthesia or critical care. Because it is a lipid emulsion, the product is a single-access parenteral item intended for use in one patient only.

Time-Bound Use: Administration must commence promptly and be completed within 12 hours after the vial is opened or the administration line is spiked. Any remaining product, tubing, or diluted solution must be discarded at the end of the procedure or after the 12-hour limit is reached.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lipofol

Clinical research for Lipofol (Propofol) includes Randomized Controlled Trials (RCTs) and systematic reviews that focus on its application as an intravenous general anesthetic and sedative. These studies monitored patient responses over defined time intervals to understand short-term changes during procedures and critical care.


Evidence for Induction and Maintenance of General Anesthesia

Research examined Lipofol’s use in patients undergoing procedures that require controlled unconsciousness. The studies focused on adults and children, often comparing Lipofol to other anesthetic agents. These trials monitored outcomes such as the time needed for a patient to lose consciousness (induction) and the short measured time to recovery once the medicine was stopped.

Studies consistently reported measurements indicating a short time to onset of unconsciousness. Findings describe patterns observed in these studies where patients typically had a measured time to meet hospital discharge criteria within a short interval after short procedures. However, there is limited information for long-term outcomes regarding any potential effects on neurological or cognitive function following general anesthesia.


Evidence for Sustained Deep Sedation in Critical Care

Lipofol was also studied for use in critical care conditions, such as continuous intravenous sedation for patients requiring mechanical ventilation. These studies monitored physiological strain or stress, including measures related to the duration of mechanical ventilation and the length of stay in the Intensive Care Unit (ICU).

Research highlights changes measured during the study period, with studies reporting how outcomes evolved in the observed populations. Data for certain subgroups remain insufficient, and research on long-term survival and overall functional recovery after discharge from the ICU is limited and heterogeneous.


What Research Remains Uncertain or Limited

Research provides context but not individual predictions, and the existing evidence highlights what is known—and what is still uncertain. Key limitations include short follow-up durations across most studies, which limits understanding of long-term outcomes. Additionally, while overall evidence is comprehensive for acute use, the data for outcomes related to systemic or functional imbalance in certain specific high-risk subgroups of the critically ill may still be considered insufficient.

Key Studies & References Propofol - StatPearls (Source for clinical context, rapid onset/recovery, and general indications)

Frequently Asked Questions (FAQ)

Common questions about Lipofol (FAQ)


Q: Is Lipofol the same type of medicine as [Common Similar Drug Name]?

A: Official documents classify the active ingredient in Lipofol, Propofol, as a non-barbiturate compound. It belongs to the class of synthetic phenolic derivatives used for general anesthesia and sedation. The official classification provides context for its chemical structure and effect profile among anesthetic agents.


Q: How quickly is Lipofol expected to start working?

A: Regulatory information and clinical studies report a short time to the onset of unconsciousness following intravenous administration. This rapid effect is a key characteristic of the medicine defined in clinical research.


Q: Is it necessary to change my diet while taking Lipofol?

A: Because Lipofol is formulated as a lipid (fat) emulsion, official warnings advise caution in patients with disorders of fat metabolism. For individuals with these conditions, careful monitoring of blood lipid levels is typically indicated by regulatory safety information. This precaution is related to the ingredients required to deliver the medicine effectively.


Q: Are the side effects of Lipofol usually temporary?

A: The official safety profile notes that certain common reactions, such as transient apnea (temporary cessation of breathing), are brief. For longer or extended use, like in critical care sedation, the time needed for the body to clear the medicine from circulation is generally longer compared to short procedures.


Q: Can people with liver problems use Lipofol?

A: Official warnings related to drug interactions state that co-administration with certain other medicines can enhance the potential for hepatotoxicity (liver damage). Specific use or restrictions related to pre-existing liver conditions are determined by the administering medical team based on a patient's clinical profile.


Q: Do studies show that Lipofol works better for some patient groups than others?

A: Official documents note that while overall evidence is comprehensive for acute use, the data for outcomes related to systemic or functional imbalance in specific high-risk patient subgroups may still be limited or heterogeneous. The existing evidence indicates that definitive conclusions about differential effects are not yet available for all populations.


Q: Does Lipofol cause 'brain fog' or affect concentration?

A: Regulatory documents include the possibility of effects on neurological or cognitive function, particularly noting that long-term outcome data in this area is limited. Patients are advised by safety documents to wait until the neurological effects have fully passed before resuming complex activities.


Q: Why might a doctor choose Lipofol over another treatment option?

A: Research has highlighted benefits that influence its selection, such as a short measured time to recovery and a rapid onset of unconsciousness compared to other agents. This rapid action is a recognized factor for its use in time-sensitive procedures.


Q: Does Lipofol have an effect on sleep patterns?

A: The medication is classified as a sedative-hypnotic agent and works by strongly depressing the central nervous system. However, specific long-term changes to a person's sleep patterns are generally not listed as a reported adverse reaction on regulatory labels.


Q: Are there any known issues with taking Lipofol and alcohol?

A: Official warnings advise that consuming alcohol can increase the nervous system side effects of the medicine, such as drowsiness, dizziness, and difficulty concentrating. This is due to both substances having a depressant effect on the central nervous system.


Q: How is Lipofol typically eliminated from the body?

A: According to official product information, the active ingredient is primarily metabolized in the liver into inactive, water-soluble substances. These metabolites are then eliminated from the body mainly through the urine.


Q: Is Lipofol an addictive or habit-forming medicine?

A: Lipofol (Propofol) is currently not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). While abuse and dependence have been documented in high-risk professional settings, the official classification does not label it as a controlled substance that requires scheduling.


Q: Is it safe to drive or operate machinery while taking Lipofol?

A: Official warnings advise patients to refrain from driving or operating machinery until the effects of the medication have fully passed. The drug can temporarily affect coordination and reaction time.


Q: Does Lipofol interact with any common vitamins or mineral supplements?

A: Regulatory documents indicate that the potential for urinary zinc loss during prolonged infusion may require the healthcare provider to evaluate the need for zinc supplementation. This is due to documented reports of urinary zinc loss associated with extended use.


Q: Are there any specific foods that should be avoided while on Lipofol?

A: The medicine is formulated as an emulsion that contains components derived from soybean and egg products. For this reason, use is contraindicated in patients with a known hypersensitivity or allergy to these components.


Q: Can Lipofol affect the results of lab tests, like blood work?

A: Official safety information notes that Lipofol can lead to changes in blood chemistry, such as high blood acid levels (known as metabolic acidosis), and requires monitoring of blood lipid levels. These changes are typically monitored through lab tests.


Q: Is it normal to feel a change in appetite after starting Lipofol?

A: Some evidence from clinical research indicates that the medication may stimulate appetite or cause feelings of hunger in the post-operative recovery period. This potential effect is not consistently listed as a formal adverse reaction on regulatory labels.


Q: Can people with kidney problems use Lipofol?

A: Official safety information notes that Propofol can be associated with severe metabolic side effects, including renal failure (kidney injury). For this reason, monitoring of kidney function is typically indicated when the medication is administered.


Q: Is a generic version of Lipofol available?

A: Yes, the U.S. Food and Drug Administration (FDA) has officially approved generic versions of Propofol, the active ingredient in Lipofol.


Q: What is the difference between the various strengths (mg) of Lipofol?

A: The medication is typically manufactured and supplied as a single, standard concentration, such as a 10 mg/mL injectable emulsion. The patient's administered dose is carefully determined by the healthcare provider based on the individual's weight and the desired level of effect.


Q: Is there a known reversal agent for Lipofol in case of an overdose?

A: Official safety documents state clearly that there is no known reversal agent (antidote) available for the effects of Propofol. The management of overdose or over-sedation is generally focused on supportive care for breathing and blood circulation.


Q: Does Lipofol need to be taken with food or on an empty stomach?

A: Since the medicine is administered intravenously (into a vein) in a controlled setting, it is not taken orally with food. Instead, patients are typically required to fast (avoid food and clear liquids) for several hours prior to the medical procedure.


Q: Can people with diabetes take Lipofol?

A: Official warnings advise caution for patients with lipid disorders, such as diabetic hyperlipemia. This is due to the medicine being formulated as a lipid emulsion, requiring monitoring and sometimes adjustment in these situations.


Q: Are there any restrictions on activity while taking Lipofol?

A: Activity is restricted during and after administration. Patients are specifically cautioned against activities requiring mental alertness, such as driving or operating machinery, until the effects of the medicine have fully passed.


Q: What does 'contraindicated' mean in the context of Lipofol?

A: In the context of drug safety, a contraindication is an official statement that the drug must not be used in a specific situation, condition, or patient group because the risk outweighs any potential benefit. The official label provides a list of these specific situations.


Q: How long does it take for Lipofol to be completely out of my system?

A: The medicine is quickly metabolized by the body. However, the time for it to be completely eliminated from the system is highly dependent on the dose, the duration of the infusion, and the individual patient’s metabolism.

How should Lipofol be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict rules for storing and handling Lipofol (Propofol Injectable Emulsion) to maintain the product's stability and prevent contamination.

  • Storage Temperature: Store the unopened product between 4 C and 25 C (40 F and 77 F). Do not freeze the emulsion, and containers should be shaken well before use.
  • In-Use Stability: Due to the risk of microbial contamination, strict aseptic technique must be maintained. Administration must be completed and any remaining product discarded within 12 hours of accessing the vial, which is intended for single patient use only.
  • Disposal: Unused portions and waste material must be discarded according to local regulations for pharmaceutical waste. Release of the product into the environment should be avoided due to its classification as harmful to aquatic life.
  • Child Safety: Keep all medicines out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipofol found in:

A-Z Index: